Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611000188932
Ethics application status
Not yet submitted
Date submitted
15/02/2011
Date registered
17/02/2011
Date last updated
9/03/2012
Type of registration
Prospectively registered
Titles & IDs
Public title
Genetic markers for ACE inhibitor associated angioedema
Query!
Scientific title
Genetic analysis for C-2399A polymorphism of the XPNPEP2 gene in patients who have had ACE inhibitor associated angioedema compared to those without and healthy population control subjects - an observational study.
Query!
Secondary ID [1]
253450
0
nil
Query!
Universal Trial Number (UTN)
nil
Query!
Trial acronym
GMAAA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Angioedema - ACE inhibitor associated
261001
0
Query!
Condition category
Condition code
Inflammatory and Immune System
259136
259136
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Study subjects will have had an episode of ACE inhibitor angioedema. This may have occured at some time in the past from 2005 to the present, or in the future. Cases will be identified from the Immunology Clinic at the Royal Adelaide Hospital, and private clinics of immunologists working at the RAH. Cases will be collected prospectively until a total of approximately 40 have been collected. Buccal cheek swabs will be used to obtain material for genetic analysis. Genetic analysis will be conducted to determine the frequency of occurrence of the C-2399A SNP of the XPNPEP2 gene. These cases will be compared with a control group, who have not had ACE inhibitor associated angioedema, who will be collected prospectively 2010 and ongoing. This is a genetic study, so samples will be collected at a single point in time. Individual patients will not be observed over a period of time.
Query!
Intervention code [1]
257892
0
Not applicable
Query!
Comparator / control treatment
Frequency of occurrence of the C-2399A SNP will also be calculated in a group of patients who have been exposed to ACE inhibitors, but who have not had ACE inhibitor angioedema. These patients will be collected prospectively. A sample for genetic analysis will be taken at a single point in time, so individual patients will not be followed over time.
Comparison will also be made with population samples, from healthy population, available in an existing DNA bank. These samples have already been collected.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
261988
0
frequency of single nucleotide polymorphism C-2339A of XPNPEP2 gene
Query!
Assessment method [1]
261988
0
Query!
Timepoint [1]
261988
0
This is a genetic study, looking a genetic variants between the study groups. As such, the outcome for each patient will only be measured once in the course of the study, as it is not expected that the genetic findings will vary over time.
Query!
Secondary outcome [1]
268920
0
nil
Query!
Assessment method [1]
268920
0
Query!
Timepoint [1]
268920
0
nil
Query!
Eligibility
Key inclusion criteria
patients with a history of ACE inhibitor associated angioedema
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
90
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
angioedema due to other pathology ie C1 esterase inhibitor defiency, food or other drug allergy
Query!
Study design
Purpose
Screening
Query!
Duration
Cross-sectional
Query!
Selection
Case control
Query!
Timing
Both
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/03/2011
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
160
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
258368
0
Self funded/Unfunded
Query!
Name [1]
258368
0
Query!
Address [1]
258368
0
Query!
Country [1]
258368
0
Query!
Primary sponsor type
Hospital
Query!
Name
Royal Adelaide Hospital
Query!
Address
North Terrace
Adelaide 5000
South Australia
Query!
Country
Australia
Query!
Secondary sponsor category [1]
257513
0
University
Query!
Name [1]
257513
0
University of Adelaide
Query!
Address [1]
257513
0
Department of Clinical and Experimental Pharmacology
North Terrace
Adelaide 5000
Query!
Country [1]
257513
0
Australia
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
260336
0
Query!
Ethics committee address [1]
260336
0
Query!
Ethics committee country [1]
260336
0
Query!
Date submitted for ethics approval [1]
260336
0
10/02/2011
Query!
Approval date [1]
260336
0
Query!
Ethics approval number [1]
260336
0
Query!
Summary
Brief summary
ACE inhibitors are a widely prescribed class of medications in Australia with established benefits in reducing mortality in a range of cardiovascular, endocrine and renal conditions. They are generally well tolerated in many patients, although they are assoicated with a range of adverse effects. One of these adverse effects is angioedema, which usually presents as non-pitting oedema of the subcutaneous tissues, usually around the head and neck. Occassionally airway obstruction may occur. While there are some recognised risk factors for ACE inhibitor associated angioedema, it is not possible to prospectively identify patients at particular risk. Improved methods to identify patients at risk may be useful to improve drug safety. One small study has identified a genetic marker, the single-nucleotide polymorphism, C-2399A of the XPNPEP2 gene which encodes plasma aminopeptidase P, for increased risk of ACE inhibitor associated angioedema. This study attempts to confirm the previous study and investigate the frequency of this genetic variant in the Australian population. We aim to enroll 40 patients who have had an episode of ACE inhibitor associated angioedema, and compare the frequency of the genetic variant in these patients with 120 control patients who have been exposed to ACE inhibitor, but have not had angioedema. We will also compare the frequency in a population sample, from healthy people.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
32117
0
Query!
Address
32117
0
Query!
Country
32117
0
Query!
Phone
32117
0
Query!
Fax
32117
0
Query!
Email
32117
0
Query!
Contact person for public queries
Name
15364
0
Dr Genevieve Gabb
Query!
Address
15364
0
VMO Office, Level 8 North Wing
Royal Adelaide Hospital
North Terrace
Adelaide 5000
South Australia
Query!
Country
15364
0
Australia
Query!
Phone
15364
0
+61 8 82224613
Query!
Fax
15364
0
+61 8 82225900
Query!
Email
15364
0
[email protected]
Query!
Contact person for scientific queries
Name
6292
0
Professor Andrew Somogyi
Query!
Address
6292
0
Discipline of Pharmacology
The University of Adelaide
North Terrace
Adelaide 5000
South Australia
Query!
Country
6292
0
Australia
Query!
Phone
6292
0
+61 8 83035572
Query!
Fax
6292
0
Query!
Email
6292
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF